CYP17A1 polymorphism c.-362T & gt;C predicts clinical outcome in metastatic castration-resistance prostate cancer patients treated with abiraterone
ConclusionsThese findings suggest an association between CYP17A1 c.-362T>C polymorphism and poorer clinical outcome with abiraterone for mCRPC patients. However, further validations on larger cohort of patients are needed to confirm its role as a predictive biomarker for abiraterone resistance.
Source: Cancer Chemotherapy and Pharmacology - Category: Cancer & Oncology Source Type: research
More News: Cancer | Cancer & Oncology | Chemotherapy | Drugs & Pharmacology | Genetics | Hormonal Therapy | Hormones | Prostate Cancer | Study